Loading
EIK1003, formerly IMP1734, is an experimental pill that blocks the PARP1 DNA-repair enzyme.
Eikon identifies EIK1003 as the former IMP1734 programme. NCT06253130 is a recruiting phase 1/2 study in advanced solid tumours. The sponsor describes PARP1 selectivity; this does not establish clinical superiority or an approved biomarker population. The asset and its licensing alias are one programme, distinct from EIK1004/IMP1707 and the WRN inhibitor EIK1005.
PARP1-selective inhibitor and trapper, licensed as EIK1003. Connects to PARP.
1.IMP1734 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"IMP1734" OR ABSTRACT:"IMP1734" OR TITLE:"EIK1003" OR ABSTRACT:"EIK1003") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about IMP1734, not a curated reading list.
Shares Eikon Therapeutics and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares PARP and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Shares Metastatic cancer (cancer that has spread) and the tags pipeline, registry-only.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/